Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
73%
Retrospective Cohort Study
66%
Adult T-Cell Leukemia/Lymphoma
65%
Diseases
57%
Overall Survival
56%
Radiation Therapy
53%
Risk Stratification
48%
Large-Cell Lymphoma
43%
Clinical Feature
42%
Infectious Complication
40%
Infection
39%
Epstein Barr Virus
37%
Hazard Ratio
34%
Malignant Neoplasm
34%
Human T-Lymphotropic Virus 1
33%
Progression Free Survival
28%
Virus
28%
Systematic Review
26%
Breast Implant
26%
Lymphoproliferative Disease
26%
Peripheral T-Cell Lymphoma
26%
MALT Lymphoma
26%
Cyclophosphamide
22%
Zidovudine
21%
Survival Rate
20%
Adverse Event
19%
Prednisone
18%
Immunity
16%
T Cell
16%
Plasmablastic Lymphoma
16%
Epstein-Barr Virus Infection
16%
Low Drug Dose
16%
Neutrophil
16%
Lymphocyte
16%
Arm
15%
Odds Ratio
15%
Cervical Cancer
14%
Rituximab
13%
Retrospective Study
13%
Tyrosine-Kinase Inhibitor
13%
Waldenström's Macroglobulinemia
13%
Cohort Effect
13%
Leukemia Cell
13%
Adolescence
13%
Epidemiology
13%
Corticosteroid
13%
Stomach Mucosa
13%
Prospective Cohort Study
13%
Prevalence
13%
Anaplastic Lymphoma Kinase
13%
Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Risk Stratification
44%
Adult T-cell Leukemia
41%
Risk Management
40%
Latin America (LATAM)
40%
Epstein-Barr Virus
32%
Large B-cell Lymphoma
30%
Clinical Features
30%
Complete Response
29%
Human T-cell Leukemia Virus Type 1 (HTLV-1)
28%
Single Center
28%
Retrospective Cohort Study
27%
Peripheral T-cell Lymphoma
26%
Not Otherwise Specified
26%
B-cell Lymphoproliferative Disorder
26%
Infectious Complications
26%
Breast Implants
26%
Older Adults
26%
Radiotherapy
24%
Lymphoma
22%
Cyclophosphamide
21%
Epstein-Barr Virus-positive
20%
Progression-free Survival
20%
Clinical Outcomes
19%
Hazard Ratio
18%
Prednisone
17%
Confidence Interval
17%
Ultra-low Dose
17%
Plasmablastic Lymphoma
17%
Epstein-Barr Virus Infections
17%
Latin American
16%
Prognostic Role
15%
Relapsed or Refractory
15%
Matched Cohort Study
15%
Odds Ratio
15%
Immunophenotyping
14%
Overall Survival
14%
5-year Survival
13%
Cause-specific
13%
Concurrent Radiation
13%
Nonmalignant
13%
Real-world Outcomes
13%
Cutaneous Involvement
13%
Multi-institutional
13%
Red Cell Distribution Width
13%
Cyclosporine
13%
Radiation Therapy
13%
Hematological Diseases
13%
Phase II Study
13%
Leukemia-lymphoma
13%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
66%
Overall Survival
45%
Clinical Feature
42%
T Cell Leukemia
41%
Infectious Complication
40%
Diffuse Large B Cell Lymphoma
40%
Infection
37%
Diseases
37%
Progression Free Survival
32%
Human T-Lymphotropic Virus 1
28%
Cyclophosphamide
22%
Zidovudine
21%
Survival Rate
20%
Prednisone
18%
Chemotherapy
15%
Retrospective Study
13%
Immunosuppressive Agent
13%
Leukemia
13%
Ciclosporin
13%
Prospective Cohort Study
13%
Multiple Myeloma
13%
Peripheral T Cell Lymphoma
13%
Brentuximab Vedotin
13%
Antimetabolite
13%
Prevalence
13%
Corticosteroid
13%
Waldenstroem macroglobulinemia
13%
Anaplastic Large Cell Lymphoma
13%
Aeromonas sobria
13%
Epstein Barr Virus Infection
13%
Uterine Cervix Cancer
13%
Rituximab
11%
Pneumocystis jiroveci
10%
Vincristine
8%
Biological Marker
8%
Alpha Interferon
8%
Doxorubicin
8%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
8%
Epstein-Barr Virus
7%
Antiinfective Agent
6%
Opportunistic Infection
6%
Strongyloides stercoralis
6%
Progressive Multifocal Leukoencephalopathy
6%
Eculizumab
6%
Antibiotic Prophylaxis
6%
B Cell Lymphoma
5%
Bacterial Infection
5%